Analogues of DNA minor groove cross-linking agents incorporating aminoCBI, an amino derivative of the duocarmycins: Synthesis, cytotoxicity, and potential as payloads for antibody-drug conjugates

  • Bioorg Med Chem. 2016 Nov 15;24(22):6075-6081. doi: 10.1016/j.bmc.2016.09.068.
Anna C Giddens  1 Ho H Lee  1 Guo-Liang Lu  1 Christian K Miller  1 Jun Guo  2 Gail D Lewis Phillips  2 Thomas H Pillow  2 Moana Tercel  3
Affiliations
  • 1. Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
  • 2. Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
  • 3. Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand. Electronic address: [email protected].
Abstract

A Pd-catalysed amination method is used to convert seco-CBI, a synthetic analogue of the alkylating subunit of the duocarmycin natural products, from the phenol to amino form. This allows efficient enantioselective access to the more potent S enantiomer of aminoCBI and its incorporation into analogues of DNA minor groove cross-linking agents. Evaluation in a panel of nine human tumour cell lines shows that the bifunctional agents containing aminoCBI are generally less cytotoxic than their phenolCBI analogues and more susceptible to P-glycoprotein-mediated resistance. However, all bifunctional agents are potent cytotoxins, some in the sub-pM IC50 range, with in vitro properties that compare favourably with established microtubule-targeted ADC payloads.

Keywords
AminoCBI; Antibody–drug conjugate; DNA cross-linking agent; Duocarmycin; Pyrrolobenzodiazepine.
Products